Compare Crispr Therapeutics AG (CRSP) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Li Auto Inc — how do they compare? Crispr Therapeutics AG trades at $50.02 (market cap $4.97B), while Li Auto Inc trades at $12.76 (market cap $12.25B). The key difference: Li Auto Inc is far larger — about 2.5× Crispr Therapeutics AG's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals.
| CRSP | LI | |
|---|---|---|
Market Cap | $4.97B | $12.25B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $31.80 |
52-Week Low | $44.34 | $11.74 |
Enterprise Value | $3.32B | $1.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Li Auto (LI) trades at $12.18, down 0.66% on the day, with a bearish technical signal and mixed earnings history. The company reported a net income margin of -1.66% for 2025 and faces headwinds from domestic competition and aggressive discounting. Recent news highlights delivery updates and new model launches, but the stock remains under pressure amid broader EV sector challenges.
The outlook is cautious with a consensus price target of $14.80, suggesting potential upside, but risks include profitability concerns, competitive pressures, and volatile cash flows. Recovery hinges on successful execution of the L series and global expansion, with FY2025-2026 seen as trough years before potential improvement from 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
